Introduction
============

Individual carriers of a premutation allele in the *FMR1* gene (55--200 CGG repeats) are at risk of developing Fragile X-associated tremor/ataxia syndrome (FXTAS) a late onset neurodegenerative disorder characterized by intentional tremor, gait ataxia, autonomic dysfunction, and Parkinsonism ([@B25]). Cognitive decline, particularly frontal executive dysfunction, is also very common ([@B2]; [@B7]). Approximately 46% of males and 17% of females will develop and be affected by FXTAS during their lifetime. The onset of the motor signs in men is typically in the early 60s ([@B23]) and the penetrance is age-related, such that 75% of men ≥80 years of age are affected ([@B13]). Patients with FXTAS have several types of motor dysfunction, hence they are considered within the combinational movement disorders ([@B11]).

A higher frequency of a number of phenotypes including psychiatric conditions, dysautonomia, sleep apnea, hypertension, migraine, rheumatologic conditions, endocrine diseases, seizures, peripheral neuropathy, immune mediated conditions (such as fibromyalgia and hypothyroidism) has also been described in premutation carriers (reviewed in [@B9]).

Several molecular mechanisms have been proposed to contribute to the different phenotypes observed in the *FMR1*- associated disorders. One of the main mechanisms proposed to lead to the premutation pathogenesis is RNA toxicity due to the 2 to 8-fold increase in the *FMR1* mRNA expression levels observed in premutation carriers ([@B24]; [@B15]; [@B3]). RNA toxicity leads to protein sequestration where the expanded CGG repeat sequesters a number of CGG binding proteins, hence, partially or fully impairing their normal function in the cell ([@B8]). Recently, a non-AUG initiated (RAN) translation, where a polyglycine-containing protein, FMRpolyG is generated by initiating at non-AUG codons located upstream of the CGG-repeat region ([@B27]), has been proposed as a key mechanism contributing to neurodegeneration. Further, DNA damage has been proposed as a pathological model due to the formation of co-transcriptional R-loops which trigger a DNA damage response (DDR) leadings to neuronal death ([@B6]; [@B12]; [@B19]; [@B14]).

In an effort to elucidate other mechanistic pathways that might be involved in FXTAS, [@B17] identified a novel gene, the antisense *FMR1* (*ASFMR1*), the main identified non-coding RNA (ncRNA) at the *FMR1* locus. The gene includes the CGG repeat region of the *FMR1* gene in the antisense orientation. Its expression is driven by two promoters that are flanked by CTCF-binding sites, the *FMR1* bidirectional promoter and a second one located in the second intron of the *FMR1* gene ([@B17]). Similarly, to the *FMR1* gene, the levels of expression of *ASFMR1* mRNA are elevated in the cells derived from premutation carriers compared to controls ([@B17]; [@B18]) while no expression is detected in patients with Fragile X syndrome. Furthermore, the *ASFMR1* transcript undergoes to premutation-specific alternative splicing which might be potentially associated with FXTAS and other *FMR1* associated disorders ([@B17]; [@B10]).

[@B18] showed that the elevated sense/antisense *FMR1* transcript levels in the gray zone (40--54 CGG repeats) and in premutation carriers might contribute to the development of a parkinsonian phenotype due to mitochondrial dysfunction that leads to progressive neurodegeneration. A recent study by [@B10] showed that both male and female premutation carriers had higher expression levels of *ASFMR1* splice isoform corresponding to the isoform described by [@B17], compared to controls after adjusting for age, confirming previous finding [@B17]. Although the authors suggested *ASFMR1* splice isoform as a predictor of FXTAS, they reported that there was no significant difference in the expression levels between non-FXTAS premutation carriers and FXTAS patients ([@B10]).

Besides the molecular measures, clinical measures have a significant role in monitoring premutation carriers with and without FXTAS. A computerized coordination-tremor-balance test system (CATSYS) is one of the important clinical assessments for FXTAS. It is a quantitative neurological test battery used to quantify movement abnormalities (tremor and ataxia) recording five main neuromotor control measures. Previous studies reported on the sensitivity of the test in identifying preclinical symptoms of FXTAS ([@B2]) and on its ability to differentiate between premutation carriers with FXTAS and controls ([@B1]; [@B20]).

In this study, we investigated the correlation between levels of mRNA expression of the *FMR1* locus (mRNA expression levels of the *FMR1* and of the *ASFMR1* genes and of the *ASFMR1* 131 bp splice isoform) and a selected group of measures in the CATSYS associated with the core symptoms of FXTAS (tremor and balance) in the non-FXTAS premutation carriers compared to controls. In addition, we investigated whether there was a differential transcript profile at the *FMR1* locus expression between premutation carriers with and without FXTAS compared to controls. The main aim of the study was to determine whether a combination of neurological and molecular measures could help predict the prognosis of non-FXTAS male premutation carriers.

Materials and Methods {#s1}
=====================

Participants
------------

Individuals were recruited through the MIND Institute Fragile X Research and Treatment Center, by postings in the community, from flyers posted through the National Fragile X Foundation, from over 1,200 extended pedigrees of probands with Fragile X-associated disorders seen for clinical care or for being participants in research studies involving non-FXTAS premutation carriers, carried out at the MIND Institute. Participants provided informed consent according to protocols approved by the UC Davis Institutional Review Board. Biological samples were collected under protocols approved by the UC Davis Institutional Review Board.

Participants included 52 non-FXTAS male premutation carriers (mean age = 59.3, *SD* = 8.3) and 26 healthy controls (mean age = 55.6, *SD* = 8.7) (**Table [1](#T1){ref-type="table"}**).

###### 

Patient demographics by group.

                              Control (*n* = 26)   Premutation (*n* = 52)   *p*-value   Adjusted *p*-value
  --------------------------- -------------------- ------------------------ ----------- --------------------
  Age (years)                                                               0.1488      0.4408
  *N*                         26                   46                                   
  Mean (*SD*)                 55.6 (8.7)           59.3 (8.3)                           
  Median (range)              55.5 (40-68)         61 (40-78)                           
  Primary race (n, %)                                                       0.4408      0.4408
  Asian                       1 (3.8%)             1 (1.9%)                             
  Black or African American   1 (3.8%)             0                                    
  White                       22 (84.6%)           42 (80.8%)                           
  Not reported                2 (7.7%)             9 (17.3%)                            
  Primary ethnicity                                                         0.3588      0.4408
  Hispanic or Latino          3 (11.5%)            2 (3.8%)                             
  Not hispanic or latino      18 (69.2%)           32 (61.5%)                           
  Not reported                5 (19.2%)            18 (34.6%)                           
  Handedness                                                                0.2442      0.4408
  Right                       22 (84.6%)           43 (82.7%)                           
  Left                        4 (15.4%)            3 (5.8%)                             
  Not reported                0                    6 (11.5%)                            
  Education level                                                           0.3798      0.4408
  High school/GED             2 (7.7%)             2 (3.8%)                             
  Partial college             3 (11.5%)            11 (21.2%)                           
  BA/BS                       11 (42.3%)           12 (23.1%)                           
  MA/MS/PhD/MD                10 (38.5%)           20 (38.5%)                           
  Not reported                0                    7 (13.5%)                            
  Yearly household income                                                   0.2827      0.4408
  25--50 K                    2 (7.7%)             2 (3.8%)                             
  50--75 K                    2 (7.7%)             7 (13.5%)                            
  75--100 K                   5 (19.2%)            4 (7.7%)                             
  100--150 K                  8 (30.8%)            12 (23.1%)                           
  150--250 K                  5 (19.2%)            6 (11.5%)                            
  \>250 K                     1 (3.8%)             9 (17.3%)                            
  Not reported                3 (11.5%)            12 (23.1%)                           
  Marital status                                                            0.0728      0.4408
  Married/partner             19 (73.1%)           42 (80.8%)                           
  Divorced                    2 (7.7%)             2 (3.8%)                             
  Single                      4 (15.4%)            1 (1.9%)                             
  Not reported                1 (3.8%)             7 (13.5%)                            

In addition, we investigated the difference in expression levels of transcripts at the *FMR1* locus in 15 trios. Each trio was age-matched, and included a male premutation carrier with FXTAS (FXTAS stage 4 or 5) (*n* = 15), a non-FXTAS male premutation carrier (FXTAS stage 0 or 1) (*n* = 15) and a healthy control (*n* = 15) (total of 45 participants).

Group status for each participant was confirmed through DNA testing as having 55--200 CGG repeats (carriers of the *FMR1* premutation), or having 5--44 CGG repeats (normal range, comparison group). Individuals who had a gray zone allele (45--54 CGG repeats) or a full mutation (\<200 CGG repeats) were not included in this study.

Clinical Measures
-----------------

CATSYS included various tasks grouped into five existing categories ([@B4]): postural tremor, intentional tremor, postural sway, manual coordination, and reaction time. All tasks were appended to the standard CATSYS protocol and analyzed accordingly.

The CATSYS measures were administered as described in [@B1]. Postural tremor was measured per the CATSYS protocol. For both dominant and non-dominant hands, the patient was asked to grasp a Tremor Pen^®^ (it contains a biaxial micro-accelerometer to measure the movement in plane perpendicular to the axis of the pen) and hold it as steadily as possible four inches in front of the navel. For the intention tremor performance task, the patient was asked to grip the pen in the same way as in the postural tremor task, yet not in a steady position, but to alternately tap the centers of two points located on either side of the computer screen, designated as points A and B, for each hand.

As for the postural sway protocol, patients were asked to stand on the force plate for 30 and 10 s, once with the eyes open and once closed. Manual hand coordination was measured by asking patients to rhythmically tap the drum in time with sounds generated by the CATSYS program. The testing using this category was completed with assessing the finger coordination, which included the rhythmic tapping of the right and left index finger. Finally, the reaction time for response, which was an auditory stimulus, in this case was recorded using the reaction handle of the CATSYS system. The duration for testing each hand was 40 s where the auditory stimuli were triggered at random intervals.

Molecular Measures
------------------

### DNA and RNA Isolation

Genomic DNA was isolated from peripheral blood lymphocytes (5 ml of whole blood using standard methods; Qiagen, Valencia, CA, United States). The CGG size of the premutation and normal alleles were obtained using a combination of Southern Blot and PCR analysis. For Southern blot analysis, 5--10 μg of isolated genomic DNA was digested with EcoRI and NruI. Probe hybridization used the FMR1-specific dig-labeled StB12.3. Details are as previously described ([@B26]). PCR analysis was performed using the AmplideX PCR/CE *FMR1* Reagents (Asuragen, Inc.) as described in [@B5]. Total RNA was isolated from 2.5 ml of peripheral blood collected in PAXgene Blood RNA tubes using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA, United States) and quantified using NanoDrop. cDNA synthesis reaction was as described by [@B24].

### Measures of mRNA Expression Levels by qRT-PCR

qRT-PCR was performed using both Assays-on-Demand from Applied Biosystem (Applied Biosystems, Foster City, CA, United States) and custom designed TaqMan primers and probe assays to measure transcripts expression levels. Custom designed primers and probe were used for normalization ([@B24]). Custom designed primers and probe were also designed to quantify the *ASFMR1* gene and the *ASFMR1* splice isoform ([@B17]).

Statistical Analysis
--------------------

Left- and right-handed clinical measures were converted to dominant and non-dominant based on the patient's handedness; if handedness information was missing measures from the right hand were used for the dominant side. A patient with a CGG repeat ranging from 110 to 130 was assigned a repeat length of 120 for analysis purposes.

By visual inspection, CATSYS data deviated substantially from a normal distribution both on the original scale and on the log scale (other transformations were not considered, as model coefficients estimated based on these are rather less interpretable than the aforementioned scales). Therefore, non-parametric methods were used throughout for analysis of these data.

Age, clinical measures, and molecular measures were compared between groups using Wilcoxon rank sum tests. Distributions of categorical demographic characteristics were compared between groups using Fisher's exact test. Correlations were estimated and tested using the Spearman (non-parametric) correlation. Clinical measures were compared between visits using the Wilcoxon signed-rank test.

In the trios study, expression levels of *ASFMR1*, the splice isoform, and *FMR1* were compared among premutation participants with FXTAS, premutation participants with non-FXTAS, and control subjects using linear models. Age and CGG repeat number were adjusted for by including these as covariates in each model. *Post hoc* pairwise comparisons between groups were conducted using the Tukey HSD method. Analyses were conducted using R, version 3.4.2 ([@B21]).

*p*-values were adjusted for multiple testing within each table using the Benjamini--Hochberg method.

Results
=======

Demographics
------------

In this study, among the total 78 subjects, 82.1% (*n* = 64) were Caucasian and 38.5% (*n* = 30) had a higher degree education (MA/MS/PhD/MD). In addition, 83.3% (*n* = 65) were right hand dominant. The demographics data showed no statistical significant difference between any of the groups (**Table [1](#T1){ref-type="table"}**).

As for the trio study, participants were individually matched for CGG repeats and age; where the mean age (SD) for the 15 controls was 63 (±8.9), for the 15 FXTAS premutation carriers was 65 (±8), and for the 15 non-FXTAS premutation carriers was 62 (±8). The mean (SD) for the CGG repeat number was 98.47 (±15.8) in male premutation carriers with FXTAS, 90.27 (±22.8) in non-FXTAS premutation carriers and 29.67 (±4.4) in controls (**Table [2](#T2){ref-type="table"}**). The mean (SD) of the *FMR1* mRNA was 2.9 (±0.6) in the premutation with FXTAS, 1.9 (±1.1) in the non-FXTAS premutation and 1.4 (±0.4) in controls. The mean of the *ASFMR1* mRNA was 0.51 (±0.3) in the premutation with FXTAS, 0.53 (±0.3) in the non-FXTAS premutation and 0.3 (±0.1) in controls. The mean of the *ASFMR1* 131 bp splice isoform mRNA was 1.9 (±1.6) in the premutation with FXTAS, 1.7 (±2.1) in the non-FXTAS premutation and 0.1 (±0.1) in controls.

###### 

Trio study subjects.

  Trio \#   Category    CGG \#   Age   FXTAS stage
  --------- ----------- -------- ----- -------------
  1         FXTAS       88       64    5
            Asymp Pre   75       66    1
            Control     31       65    0
  2         FXTAS       104      56    4
            Asymp Pre   98       59    1
            Control     21       50    0
  3         FXTAS       119      67    5
            Asymp Pre   105      64    0
            Control     28       66    0
  4         FXTAS       102      69    4
            Asymp Pre   110      57    1
            Control     29       65    0
  5         FXTAS       133      54    4
            Asymp Pre   141      52    1
            Control     28       53    0
  6         FXTAS       96       61    4
            Asymp Pre   95       60    1
            Control     33       61    0
  7         FXTAS       80       79    4
            Asymp Pre   80       71    0
            Control     32       76    0
  8         FXTAS       82       57    4
            Asymp Pre   84       51    0
            Control     32       52    0
  9         FXTAS       103      58    4
            Asymp Pre   128      53    0
            Control     29       55    0
  10        FXTAS       100      56    4
            Asymp Pre   80       56    0
            Control     28       55    0
  11        FXTAS       88       66    4
            Asymp Pre   85       63    1
            Control     27       64    0
  12        FXTAS       83       70    4
            Asymp Pre   77       69    1
            Control     42       70    0
  13        FXTAS       121      76    4
            Asymp Pre   67       74    1
            Control     28       73    0
  14        FXTAS       83       75    4
            Asymp Pre   59       76    0
            Control     30       79    0
  15        FXTAS       95       66    4
            Asymp Pre   70       64    1
            Control     27       64    0

A Subset of CATSYS Clinical Measures Differentiate Between Non-FXTAS Premutation Carriers and Controls
------------------------------------------------------------------------------------------------------

Three CATSYS performance measures were found to be significantly different between non-FXTAS premutation carriers and controls; the reaction time test for dominant hand (Average reaction time) (*p* = 0.0094), the 30 s postural sway test with eyes open (*p* = 0.0176), and the 10 s postural sway test with eyes closed (*p* = 0.0094) (**Table [3](#T3){ref-type="table"}**). This means that both the reaction time and the sway area are significantly increased in non-FXTAS premutation carriers compared to controls.

###### 

CATSYS clinical measures in both normal and premutation carrier groups.

                                                                    Control         Premutation           *p*-value       Adjusted *p*-value                 
  ----------------------------------------------------------------- --------------- --------------------- --------------- --------------------- ------------ ------------
  Reaction time test for dominant hand: average reaction time       0.204 (0.02)    0.2 (0.159-0.239)     0.23 (0.032)    0.23 (0.167-0.295)    **0.0011**   **0.0094**
  Sway closed 30: sway area                                         454 (402)       403 (5-1703)          802 (580)       653 (11-2,300)        **0.0033**   **0.0176**
  Sway closed 10: sway area                                         218 (189)       198 (0-799)           500 (445)       325 (8-1,988)         **0.0012**   **0.0094**
  Reaction time test for non-dominant hand: average reaction time   0.198 (0.025)   0.198 (0.137-0.236)   0.218 (0.035)   0.212 (0.163-0.318)   **0.0463**   0.1234
  Dominant foot: sway area                                          568 (300)       570 (18-1,169)        1107 (1,001)    698 (9-4,203)         **0.0394**   0.1234
  Non-dominant foot: sway area                                      538 (452)       419 (13-1,713)        842 (672)       685 (6-3035)          **0.0287**   0.1147

Significant values are indicated in bold

.

On the other hand, a subset of measures lost their significance upon correction for multiple testing; reaction time test for non-dominant hand (average reaction time) (*p* = 0.0463), dominant foot (sway area) (*p* = 0.0394) and non-dominant foot (sway area) (*p* = 0.0287).

Impact of Age, CGG Repeat Number, Expression Levels of *FMR1*, *ASFMR1*, and *ASFMR1* Splice Isoform mRNAs on CATSYS Measures
-----------------------------------------------------------------------------------------------------------------------------

A significant correlation between the non-dominant hand tremor intensity and the *ASFMR1* 131 bp splicing isoform was observed in non-FXTAS premutation carriers (*p* = 0.0304) but not in controls (*p* = 0.3363) (**Figure [1A](#F1){ref-type="fig"}**). The expression level of *ASFMR1* 131 bp splicing isoform showed a significant inverse correlation with the non-dominant hand tremor intensity (-0.44) with the higher splicing isoform expression levels of this being associated with lower non-dominant hand tremor intensity score.

![Plots showing the correlation between the expression level of the *ASFMR1* spicing isoform 131 bp *mRNA* and tremor intensity in the non-dominant hand **(A)**, tremor intensity in the dominant hand **(B)**, and tremor intensity while writing with dominant hand **(C)** in controls compared to premutations without FXTAS.](fgene-09-00302-g001){#F1}

Correlation between *ASFMR1* 131 bp splicing and two CATSYS performance tasks, tremor intensity of dominant hand (*p* = 0.0489) (**Figure [1B](#F1){ref-type="fig"}**), and tremor intensity while writing with dominant hand (*p* = 0.0268) (**Figure [1C](#F1){ref-type="fig"}**) lost significance after correction for multiple testing.

None of the CATSYS measures showed any statistically significant association with age, CGG repeat number, expression levels of *FMR1*, or *ASFMR1* mRNAs.

Expression Levels of Transcripts at the *FMR1* Locus
----------------------------------------------------

Premutation carriers (with and without FXTAS) showed significantly elevated expression of both *FMR1* and *ASFMR1* 131 bp splicing isoform mRNA compared to controls with a *p* \< 0.0001 in both cases (**Figures [2A,C](#F2){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**). No significant elevation was observed for the *ASFMR1* mRNA (**Figure [2B](#F2){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**).

![Box plots showing the expression of *FMR1* **(A)**, *ASFMR1* **(B)**, and *ASFMR1* 131 bp splicing isoform **(C)** in premutation carriers compared to controls. Correlation between CGG repeat number and the expression levels of **(D)** *FMR1*, **(E)** *ASFMR1*, and **(F)** *ASFMR1* 131 bp splicing isoform mRNAs.](fgene-09-00302-g002){#F2}

###### 

Summary of expression by group.

                                     Normal        Premutation         *p*-Value      Adjusted *p*-value                  
  ---------------------------------- ------------- ------------------- -------------- -------------------- -------------- --------------
  *FMR1*                             1.24 (0.21)   1.25 (0.83--1.64)   2.44 (0.74)    2.29 (0.63--4.41)    **\<0.0001**   **\<0.0001**
  *ASFMR1*                           1.38 (1.09)   1.33 (0--3.64)      2.83 (5.35)    1.47 (0.14--34.29)   0.0889         \>0.9999
  *ASFMR1* 131 bp splicing isoform   0.24 (0.52)   0.02 (0--1.95)      8.14 (16.75)   2.04 (0--103.53)     **\<0.0001**   **\<0.0001**

Significant values are indicated in bold

.

None of the molecular measures were significantly correlated with age. As expected, the CGG repeat number was significantly correlated with the expression of both *FMR1* (*p* \< 0.0001) and *ASFMR1* 131 bp splicing isoform mRNAs (*p* = 0.001) (**Table [5](#T5){ref-type="table"}** and **Figures [2D](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**) but not for the *ASFMR1* mRNA (**Figure [2E](#F2){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**).

###### 

Correlations between molecular measures and CGG repeat numbers.

                                     Normal   Premutation                                    
  ---------------------------------- -------- ------------- ---------- ------ -------------- --------------
  *FMR1*                             0.13     0.542         \>0.9999   0.76   **\<0.0001**   **\<0.0001**
  *ASFMR1*                           0.03     0.8659        \>0.9999   0.09   0.5046         0.5046
  *ASFMR1* 131 bp splicing isoform   0.04     0.8424        \>0.9999   0.46   **0.0006**     **0.001**

Significant values are indicated in bold

.

When analyzing the trios, as expected we observed a significant higher expression of *FMR1* mRNA in the premutation carriers with FXTAS and without FXTAS compared to control subjects (**Figure [3A](#F3){ref-type="fig"}**; *p* \< 0.001 and *p* \< 0.001, respectively, [@B22]). In addition, we observed significantly higher expression level of *ASFMR1* 131 bp splicing isoform mRNA in both non-FXTAS premutation subjects \[*p* = 0.003, Mean (*SD*) = 1.7 (2.1)\] and subjects with FXTAS \[*p* = 0.004, Mean (*SD*) = 1.9 (1.6)\] compared to control subjects \[Mean (*SD*) = 0.1 (0.1)\] (**Figure [3C](#F3){ref-type="fig"}**). However, the *ASFMR1* expression levels between groups did not reach statistical significance (**Figure [3B](#F3){ref-type="fig"}**). These three molecular measures were significantly correlated with the number of CGG repeats (**Figures [3D](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}**).

![Box plots showing differential expression levels of *FMR1* **(A)**, *ASFMR1* **(B)** and *ASFMR1* 131 bp splicing isoform **(C)** mRNAs in controls compared to non-FXTAS premutation carriers and FXTAS premutation carriers. *FMR1, ASFMR1*, and *ASFMR1* 131 bp splicing isoform mRNAs expression levels, as function of the CGG repeat number, are shown in **D**, **E** and **F** respectively.](fgene-09-00302-g003){#F3}

Discussion
==========

This study aimed to identify clinical and molecular measures that might associate with development of FXTAS in male Fragile X premutation carriers. CATSYS is among the helpful tools to distinguish between premutation carriers with and without FXTAS and controls because it allows for quantitative documentation of neuromotor and deficits with minimal operating training and time ([@B1]). Specifically, among the measures found useful, are those that are considered components of the key FXTAS phenotypic characteristics such as tremor intensity, postural tremors, and postural sway ([@B1]; [@B20]). Our previous reports ([@B1]; [@B20]), looking specifically at the CATSYS measure in *FMR1* premutation carriers with and without FXTAS and, unaffected controls, found the method to be sufficiently accurate for the cause. In addition, the 2008 study by Allen colleagues showed a high clinical usefulness of the battery.

In this study, we showed that three CATSYS task performance measures were significantly different in non-FXTAS male premutation carriers compared to controls. Two of them were measures of postural sway, which are associated with ataxia. Our results appear to be consistent with those of [@B20], as both showed that non-FXTAS premutation carriers had higher postural sway compared to controls. However the significance of this effect was lost when correcting for multiple testing. Several factors could explain these findings including the age group of the non-FXTAS participants (mean = 59.3) compared to the mean of 52.89 in the [@B20] study. Further, gender might be another contributing factor, where [@B20] included females only, whereas, our study had males only. Hence, a subset of our subjects might be showing signs of ataxia because of being older males.

Importantly, this study aimed to identify molecular biomarkers at the *FMR1* locus (*FMR1*, *ASFMR1*, and *ASFMR1* 131 bp splicing isoform) that may correlate with early emergence of movement abnormalities in premutation carriers without FXTAS and might be helpful as potential biomarkers in longitudinal studies. We found an inverse correlation between both *ASFMR1* 131 bp splice isoform and tremor intensity for the non-dominant hand. Thus, using a combination of molecular and clinical phenotypic measures could help to identify changes in premutation carriers most at risk for developing FXTAS.

Interestingly, the expression of *ASFMR1* 131 bp splice isoform mRNA was higher in premutation carriers overall compared to controls, but it did not distinguish between non-FXTAS and FXTAS premutation carrier groups. The function, if any, of this splicing isoform is currently unknown and the dysregulation of the alternative splicing process and the levels of expression of the *ASFMR1* could be part of the pathogenesis of FXTAS as could be the case for the *FMR1* gene ([@B28]). Moreover, it was previously found that RAN translation, which is one of the mechanisms proposed to explain the pathogenesis of FXTAS, also occurs in the antisense direction generating novel proteins that accumulate in ubiquitinated inclusions in FXTAS patients ([@B16]) further supporting the potential role of the antisense transcript in FXTAS. Further studies are needed to shed lights on the significance of increased expression levels of this isoforms in premutation carriers.

This study demonstrates that sensitive postural sway and tremor tests might be used in early identification of premutation carriers at risk for FXTAS, however, future longitudinal analyses with larger sample sizes are needed to confirm this hypothesis. Objective and sensitive movement measures should also be useful for monitoring disease progression, severity, and response to intervention. Further studies are warranted to further assess the correlation between the clinical and molecular measures to confirm our observations in this study.
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